Navigation Links
ExonHit Therapeutics Shareholders' Equity Strengthened by Exercise of More Than Half of its Convertible Bonds
Date:3/8/2009

PARIS, March 9 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) today announced that 1,076,923 out of 2,080,335 convertible bonds issued November 8, 2006 and redeemable November 8, 2011 have been converted into shares.

This conversion results into a EUR 17,231 capital increase and EUR 6,982,769 increase in additional paid-in capital. At the same time, the convertible bond debt is reduced to EUR 6,522,178 compared to EUR 13,522,178 as of December 31, 2008.

Philippe Rousseau, Chief Financial Officer of ExonHit Therapeutics, said: "This transaction is good news for ExonHit, as it strengthens our balance sheet. And, while it is not providing any cash, this conversion will save us more than EUR 650,000 of interest payments over the next 32 months. "

About ExonHit Therapeutics

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit Therapeutics has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArray(TM) family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit Therapeutics has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers.

In parallel, ExonHit Therapeutics is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit Therapeutics also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ISIN: FR0004054427; ticker: ALEHT) since November 17, 2005. For more information, please visit http://www.exonhit.com.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.


'/>"/>
SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. ExonHit Therapeutics - 2007 Financial Results
7. ExonHit Appoints a New Management Board
8. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
9. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
10. Loic Maurel Joins Exonhit Therapeutics to Become CEO
11. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):